Enfusion (NYSE:ENFN) reported quarterly losses of $(2.26) per share. The company reported quarterly sales of $31.90 million which beat the analyst consensus estimate of $30.41 million by 4.90 percent.
Eli Lilly Sees FY22 Adj EPS Of $7.70-$7.85 Vs. Prior Range Of $7.90-$8.05 And $8.08 Consensus
The company forecasts FY22 sales of $28.5 billion-$29.0 billion compared to previous guidance of $28.8-$29.3 billion and a consensus of $28.27 billion
